PS1032 SURVIVAL FROM ACUTE MYELOID LEUKEMIA HAS SINCE 1997 IMPROVED ONLY IN MALES AGED 50–75 YEARS – A SWEDISH POPULATION-BASED STUDY

Background: For AML (excluding APL), there has until recently been no major changes in AML‐specific drug therapy, but improvements of supportive care and access to allogeneic transplantation (SCT). Aims: We aimed to analyze changes in survival from AML (non‐APL) over the period 1997–2016, and to identify and characterize patient subsets with greater improvement. Methods: Data from all Swedish AML‐patients, diagnosed from 1997 and reported in the...